Megakaryon
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $2.8B
Overview
Developing mass-produced, allogeneic iPSC-derived platelet transfusions to overcome donor dependency and supply shortages in hematology.
HematologyRegenerative Medicine
Technology Platform
Proprietary platform for mass-producing functional human platelets from HLA-homozygous induced pluripotent stem cells (iPSCs) via directed differentiation of megakaryocytes.
Opportunities
Addressing the global, chronic shortage of donor platelets with a scalable, standardized, and potentially safer off-the-shelf product; leveraging Sysmex's global diagnostics and healthcare network for development and commercialization.
Risk Factors
Clinical risks include demonstrating safety (particularly from residual iPSCs) and non-inferior efficacy versus donor platelets; commercial risks involve achieving cost-effective manufacturing at scale for a price-sensitive transfusion market.
Competitive Landscape
Competitors include other groups developing in vitro platelet production (e.g., PlateletBio, Arteriocyte). Megakaryon differentiates through its foundational IP from leading Japanese institutions, its HLA-homozygous iPSC strategy for broad compatibility, and the industrial/commercial backing of Sysmex.